Bioenvision Inc

Bioenvision — Merger or Acquisition (September 2007)

24 slides from Bioenvision's merger presentation, Sep 19, 2007

  1. Slide 1: Proposed Acquisition by Genzyme Corporation: Rationale and Valuation Perspectives

    Proposed Acquisition by Genzyme Corporation September 2007 Rationale and Valuation Perspectives

  2. Slide 2: Forward-looking statements

    Certain forward looking statements are included in this presentation, including statements relating to a proposed transaction by and among Bioenvision Inc., Genzyme Corporation and Wichita Bio Corporation. These statements are made pursuant to the safe harbor provisions of the Private Securities Lit

  3. Slide 3: Overview of Rationale

    Overview of Rationale The transaction is in the best interests of stockholders The transaction allows Evoltra® to be developed and commercialized more rapidly toward the advancement of human health

  4. Slide 4: Summary of Rationale

    Summary of Rationale Process The transaction process was professional and comprehensive Negotiation The transaction price was determined to be the highest price then obtainable Cash Value Certainty There is certainty in the transaction value of $5.60 per share in cash Key Terms Our Board had the abi

  5. Slide 5: Summary of Rationale (cont'd)

    Summary of Rationale (cont’d) Valuation The transaction value is fair The transaction value represents a significant premium Alternatives There are significant operating risks to going it alone Incentives Board, management and shareholders’ incentives are aligned

  6. Slide 6: Review

    Transaction Review May 29, 2007 announcement $5.60 per share Two-step merger process Transaction valued Bioenvision at $345 million Step 1: Tender period closed July 10, 2007 Genzyme purchased 22% of shares on an as-converted basis Genzyme owns all of the preferred shares and the rights appurtenant

  7. Slide 7: Company Overview

    Company Overview Product focused biopharmaceutical company with approved cancer therapeutics Lead product Evoltra ® (clofarabine) Approved in E.U. for pediatric ALL with orphan drug exclusivity through 2016 Further clinical development opportunities Pending Adult AML elderly non-intensive Adult AML

  8. Slide 8: BIVN Genzyme Co-Development Agreement

    BIVN Genzyme Co-Development Agreement Formed March 12, 2001 with Ilex Oncology to co-develop, commercialize and market purine nucleoside analogues (i.e. clofarabine) Genzyme is successor-in-interest to Ilex U.S./Canada Rights* 100% of development costs in U.S./Canada 50% of approved development cost

  9. Slide 9: Bidding Process

    Transaction Rationale – Bidding Process Genzyme was the ONLY third party that made an offer which was not subsequently withdrawn. Since 2003, potential strategic alternatives explored with multiple parties Advisor engaged in 2003; subsequent advisor, UBS, engaged in mid-2005 Prior to 2007, over 20 p

  10. Slide 10: Price Negotiation

    Transaction Rationale – Price Negotiation Based on the results of our prior efforts and our extended arm’s-length negotiations with Genzyme, our board believed that the merger consideration represented the highest price per share that was then obtainable On April 11, 2007, the Company received an of

  11. Slide 11: Key Term Negotiations

    Transaction Rationale – Key Term Negotiations Since the public announcement on May 29, 2007, when it became public that the company was for sale for at $5.60 per share, we have not received ANY indication of interest from ANY third party regarding the sale of the Company. The transaction terms allow

  12. Slide 12: Market Premium: LTM Price/Volume Performance

    Transaction Rationale – Market Premium 08/15/06 LTM Price/Volume Performance 05/31/06 Receives European approval for Evoltra 09/18/06 Announces it is expanding into Japan and Southeast Asia for the clinical and commercial development of Evoltra 11/10/06 Announces the filing of a clinical trial autho

  13. Slide 13: Market Premium

    Transaction Rationale – Market Premium Price Implied ($/Share) Premium (%) 1 Day Prior to Announcement Date (5/25/07) 5.25 6.7 Unaffected Stock Price (5/15/07) (1) 3.35 67.2 1 Week Prior to Announcement Date (5/18/07) 4.00 40.0 1 Month Prior to Announcement Date (4/25/07) 3.75 49.3 30 Trading Day Av

  14. Slide 14: Market Premium: Equity and Enterprise Value

    Transaction Rationale – Market Premium @ Unaffected (US $mm, unless otherwise noted) Stock Price (1) @ Offer Price Share Price ($/Share) 3.35 $ 5.60 $ Diluted Shares Outstanding (Treasury Method) (2) 60.9 61.5 Equity Value (4) 204 $ 345 $ Plus: Debt - $ - $ Less: Cash (3) (48) $ (48) $ Enterprise Va

  15. Slide 15: Financials and Forecast / Strategic Review

    Transaction Rationale – Financials FYE 2007 Financial Performance Revenue of $19 million 40% sold to Cardiff into AML-16 trials Operating Loss of $37.6 million Company does not provide revenue guidance (1) Forecast / Strategic Review Independent third party consultant retained Review initiated and l

  16. Slide 16: Strategic Review and Forecast

    Transaction Rationale – Strategic Review and Forecast Fiscal Year End June 30, ($000,000s) 2017 2018 2019 2020 2021 2022 Net Sales 405.1 243.1 72.9 43.8 30.6 24.5 Total Royalties 2.6 0.7 0.7 0.7 0.7 0.7 Net Sales & Royalties 407.7 243.8 73.7 44.5 31.4 25.2 Total Op. Costs (before SRI Royalty and Pro

  17. Slide 17: Revenue Multiples and Valuation

    Revenue Multiples 4.8x 4.0x 2009 7.8x 6.8x 7.8x 6.4x 2008 12.4x 8.0x 12.4x 7.6x 2007 Implied BIVN Selected Companies (Mean) Implied BIVN Selected Companies (Mean) Comparable Transactions Comparable Companies Discounted Cash Flow Reference Range For Fair Price 22.5% 17.5% Offer $3.72 $5.33 $5.60 Tran

  18. Slide 18: Street Expectations

    Transaction Rationale – Street Expectations ($mm) Report Date Price Target Revenue EBITDA AG Edwards May 18, 2007 $9.00 284.1 139.9 UBS May 17, 2007 $13.00 207.6 57.1 CIBC World Markets May 9, 2007 $9.00 170.9 75.1 Rodman & Renshaw May 9, 2007 $12.00 199.5 72.1 Fortis Bank April 3, 2007 $3.00 107.6

  19. Slide 19: Operational Risks of Going It Alone

    Transaction Rationale – Operational Risks of Going It Alone Forecast assumes mid-2008 launch in adult AML elderly non-intensive indication in Europe Adult AML filing risk of non-randomized trial and request for AML-16 data Changing standards of care as additional drugs seek approval in hematological

  20. Slide 20: Other Risks of Going It Alone

    Transaction Rationale – Other Risks of Going It Alone Absence of transaction price to maintain floor on stock price Absence of buyout premium because market has information that no alternate bidders exist at this price Genzyme preferred stock rights Macro-environment: Small cap stocks in $100 millio

  21. Slide 21: Market Reaction Drivers

    Market Reaction Drivers 1 Source: 13-D filing of SCO Capital and affiliates dated June 6, 2007 and September 12, 2007. 13-D filings of Elliott Associates and affiliates dated August 10, 2007 and September 5, 2007. 2 Source: January 8, 2002 8-K filings of the Company, and Company records. 3 Source: F

  22. Slide 22: Incentives: Board, management and shareholders aligned

    Severance Stock Options Equity $ 2.6 $ 0.09 $ 7.9 Additional Value of Hypothetical $1 Increase in Purchase Price $ 3.3 $ 0.11 - Additional In-The-Money Value of Hypothetical $1 Increase in Purchase Price $ 14.3 $ 0.5 $ 44.1 Value at $5.60 $ 1.5 (3) $ 10.4 Executive Management (2) - $ 0.08 Other Inde

  23. Slide 23: Conclusion

    Conclusion 1 The transaction is the highest 2 The transaction value represents a substantial premium when analyzed using standard valuation metrics 3 The operating and other risks of not pursuing the transaction are significant The Board and management recommend voting for approval by proxy or in pe

  24. Slide 24: Bioenvision

    bioenvision

Bioenvision — Merger or Acquisition (September 2007) on 6ix